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Abstract
Age is a powerful predictor of survival in glioblastoma multiforme (GBM) yet the biological basis for the difference in clinical
outcome is mostly unknown. Discovering genes and pathways that would explain age-specific survival difference could
generate opportunities for novel therapeutics for GBM. Here we have integrated gene expression, exon expression,
microRNA expression, copy number alteration, SNP, whole exome sequence, and DNA methylation data sets of a cohort of
GBM patients in The Cancer Genome Atlas (TCGA) project to discover age-specific signatures at the transcriptional, genetic,
and epigenetic levels and validated our findings on the REMBRANDT data set. We found major age-specific signatures at all
levels including age-specific hypermethylation in polycomb group protein target genes and the upregulation of
angiogenesis-related genes in older GBMs. These age-specific differences in GBM, which are independent of molecular
subtypes, may in part explain the preferential effects of anti-angiogenic agents in older GBM and pave the way to a better
understanding of the unique biology and clinical behavior of older versus younger GBMs.
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Introduction
Glioblastoma multiforme (GBM) is the most common malig-
nant primary brain tumor [1]. GBM patients have a median
survival of about fourteen months despite aggressive multimodality
treatment [2]. Given the pathological and clinical heterogeneous
nature of GBMs, there have been a number of recent attempts to
better understand and characterize these tumors at the molecular
and genetic level [3–16]. Among these studies, The Cancer
Genome Atlas Project (TCGA) has generated a vast amount of
high-throughput data for about 500 GBM samples [4,15].
Advanced age has been identified as an independent significant
prognostic factor for survival in glioblastoma clinical trials since
the 1970s (Table S1). An analysis of three randomized phase III
trials conducted by the Radiation Therapy Oncology Group
(RTOG) showed that median survival of GBM patients aged 60 or
older was 7.5 months compared to 16.2 months in patients
younger than 40 years old [17]. Older age as negative prognostic
factor for GBM survival was confirmed by other National Cancer
Institute sponsored cooperative groups [18,19] and a large meta-
analysis of 3,004 patients with high-grade gliomas [20]. The study
that established the current standard of care for newly diagnosed
glioblastoma with radiation and concurrent temozolomide also
showed a shorter median survival of patients older than 60 years
(11.4 months) compared to those who were 50 years or younger
(17.4 months) [21].
The reasons why older age is such a negative prognostic factor
remain unclear. Retrospective data and randomized controlled
trials do not suggest that older patients receive less than optimal
treatment and/or tolerate treatment less well than younger
patients thereby suggesting a potential difference in the biology
of GBMs in older patients. Thus, it would be valuable to discover
age-specific signatures in GBM biology that might explain this
survival difference and allow clinicians to develop age-specific
therapeutic clinical trials for GBM.
Noushmehr, et al. discovered a glioma-CpG island methylator
phenotype (G-CIMP) in GBMs [22]. G-CIMP positive patients
(about 11% of GBM samples in TCGA) have significantly longer
survival than G-CIMP negative patients. G-CIMP positive
patients are also significantly younger than G-CIMP negative
patients. Nevertheless, age still turns out to be a significant
independent prognostics factor for survival despite the G-CIMP
status of the tumor [22].
In this study, we computationally analyzed gene expression,
exon expression, microRNA expression, DNA methylation, copy
number alteration, somatic mutation derived from whole exome
sequence, and SNP data sets of the TCGA GBM samples to
discover age-specific signatures at the transcriptional, genetic, and
epigenetic levels. In order to avoid the confounding variable of the
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G-CIMP status of the tumor, we trained a model to predict G-
CIMP status of GBM samples based on gene and exon expression
profiles in order to exclude G-CIMP positive patients in our
analyses.
Materials and Methods
Determining Old and Young GBM Groups
For two-sample tests, we defined a ‘‘young’’ and ‘‘old’’ group.
We hypothesized that if there is an old and young biology then
samples with ‘‘intermediate’’ ages might represent a mix of these
biologies. Thus, we did not include samples with ‘‘intermediate’’
ages in our old and young groups. In order to define the age
boundaries for the old and young groups, we examined the
histogram of survival for different age groups (Figure S1) and
number of samples in each age group (Figure S2). We assigned
patients #40 years old to the young group and patients $70 years
old to the old group. The number of available samples in the young
and old groups changes depending on the data set (Table 1), but
overall young and old patients constitute 9% and 21% of all
samples, respectively. For linear regression tests, we also used
samples with intermediate ages (i.e., between 40 and 70) to increase
the power of the analysis.
Predicting G-CIMP Status of GBM Patients and Removing
G-CIMP Positive Patients
We obtained G-CIMP calls of samples that have methylation
data from [22] (Figure 1). To predict G-CIMP calls of samples for
which no methylation data is available, we used the k-nearest
neighbor algorithm to train models from gene and exon expression
profiles of samples with a G-CIMP call. The G-CIMP call
prediction results from models of gene and exon expression
overlapped by more than 95%. We chose consistent prediction
calls as final G-CIMP calls. All analyses were conducted on
PartekH Genomics SuiteTM version 6.5 (Copyright 2010 Partek
Inc., St. Louis, MO, USA).
G-CIMP positive patients are significantly younger than G-
CIMP negative patients and there is a significant difference
between G-CIMP positive and negative patients at the transcrip-
tional, genetic, and epigenetic levels [22]. If we compared the old
and young groups without eliminating G-CIMP positive samples,
some of the G-CIMP-specific signatures would be potentially
considered as age-specific (i.e., Type I error). In order to eliminate
this error, we excluded the G-CIMP positive samples, which
constituted about 11% of the database in our analysis.
Computing Age-specific Differentially Expressed/
methylated Genes and microRNAs
We used data sets from Affymetrix U133A, Affymetrix Human
Exon 1.0, and Agilent 244 K G4502A platforms in TCGA for
differential gene expression analysis (Table 1). We used DNA
methylation data set from Illimuna Infinium Human DNA
Methylation 27 in TCGA for differential methylation analysis
(Table 1). The sample IDs for each data set are listed in Table S2.
We used data set from Agilent 8615 K Human miRNA-specific
microarray in TCGA for differential microRNA expression
analysis (Table 1). Finally, we used 100 microRNA-specific probes
in the Illumina Infinium platform for differential microRNA
methylation analysis. We applied two-sample t-test to compute
age-specific differentially expressed genes (DEGs) between the old
and young groups. Considering age as a continuous variable, we
applied linear regression to compute age-specific DEGs. We also
applied a nonparametric ranked-based linear regression to find age-
specific differentially expressed microRNAs and differentially
methylated genes (DMGs). We used a ranked-based linear
regression on microRNA expression and DNA methylation data,
since these data were not normally distributed. We used the samr
v1.28 package in R [23] for all tests. For multiple test correction,
we applied a permutation-based FDR threshold of 0.05.
Table 1. Number of GBM samples used in this study (downloaded from the TCGA repository on June 29, 2011, Sample IDs are in
Table S1).
Data Type Platform Level1 Institute # Old2 # Young2 Total
Gene expression Affymetrix HT Human Genome
U133 Array Plate Set
2 Broad Institute of MIT and
Harvard
92 37 422
Exon expression Affymetrix Human Exon 1.0 ST
Array
3 Lawrence Berkeley National
Laboratory
80 34 382
Gene expression Agilent 244K Custom Gene
Expression G4502A
2 University of North Carolina 92 37 420
miRNA expression Agilent 8615K Human
miRNA-specific microarray
3 University of North Carolina 80 34 385
Methylation Illumina Infinium Human DNA
Methylation 27
2 Johns Hopkins/University of
Southern California
56 22 256
Copy Number Agilent Human Genome CGH
Microarray 244A
3 Memorial Sloan-Kettering
Cancer Center
87 36 406
SNP Affymetrix Genome-Wide
Human SNP Array 6.0
3 Broad Institute of MIT and
Harvard
88 32 390
SNP Illumina 550K Infinium
HumanHap550 SNP Chip
3 HudsonAlpha Institute for
Biotechnology
78 33 376
Whole Exome
Sequence
Illumina Genome Analyzer IIx N/A Broad Institute of MIT and
Harvard
55 12 202
1Level 2 refers to probeset-level data and level 3 refers to gene-level data for expression and methylation data sets. Level 3 refers to segmented data for copy number
and SNP data sets. There is no level number for whole exome sequence data set as we just used the mutations derived from this data set.
2Old and Young refer to samples $70 and #40 years old, respectively.
doi:10.1371/journal.pone.0062982.t001
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Computing Age-specific Differentially Altered Genes
We used segmented copy number/SNP data sets in Agilent HG
CGH 244 K, Affymetrix Human SNP 6.0, and Illumina 550 K
Infinium HumanHap550 platforms in TCGA (Table 1). The
samples from Agilent HG CGH 244 K data set cover all samples
in Infinium HumanHap550 data set and 95% of the samples in
SNP6 data set (Figure S3). We performed the analysis on each
data set independently. We generated a project in Nexus v5.1
(BioDiscovery Inc., El Segundo, CA, USA) for each data set and
used Nexus’ comparison function to find differentially altered regions
between old and young groups (q-value#0.05). The comparison
function compares the frequency of alteration in both groups and
finds areas where there is significant difference in frequency [24].
Somatic Mutation Data Analysis
We used somatic mutations derived from whole exome
sequences in TCGA (TCGA Analysis Working Group Data
Release Package 1, 8/26/2011). We performed Fisher’s exact test
to find genes that are significantly mutated in old or young GBMs.
Survival Analysis
We applied Cox multivariate analysis on variables namely age,
molecular subtypes derived in [15] (i.e., classical, neural,
mesenchymal, proneural), gender, and Karnofsky performance
score. We used coxph function in R [25]. We also generated
Kaplan-Meier survival plots in PartekH Genomics SuiteTM version
6.6.
Functional Analysis
We applied the gene set enrichment analysis (GSEA) algorithm
[26,27] to identify upregulated expression pathways and signatures
by comparing old and young groups. GSEA mapped all 3272 gene
sets in the functional c2 v3 MsigDB database to ranked genome-
wide expression profiles (Affymetrix U133A) of old versus young
groups. To compute p-values for enrichment scores, we applied
Kolmogorov-Smirnov statistics by constructing a cumulative null
distribution with permuting old and young group assignments
1000 times. The significant gene sets were claimed for nominal
p#0.05. We also used DAVID [28] to create functional
annotation charts on age-specific upregulated genes derived from
both Affymetrix U133A and Agilent 244 K G4502A data sets via a
linear regression method (Fisher’s exact test p#0.05) and
Ingenuity Pathway Analysis (IPA) software (IngenuityH Systems,
www.ingenuity.com) on age-specific angiogenesis related genes to
display the interactions among these genes.
Motif Enrichment Analysis
In order to compute enriched motifs in the promoters of the
age-specific DEGs, we used PScan [29] to find enriched motifs in
the JASPAR database [30]. We checked sequences from 450 bp
upstream to 50 bp downstream of the transcription start size for
each Refseq transcript of the gene in human genome version hg19.
We applied a Benjamini-Hochberg multiple test correction
method [31] to correct for multiple testing.
Cross-validation on TCGA Data Set
To validate age-specific DEGs, we applied 10-fold cross-
validation on TCGA U133A data set of old and young patients.
For each fold, we used the support vector machine (SVM)
algorithm to build a model based on training data (i.e., age-specific
DEGs obtained from 90% of samples) and used this model to
predict the old/young status of the remaining 10% of samples. For
comparison, we also used the same algorithm to build a model
based on the molecular subtype-specific DEGs of training data.
We used PartekH Genomics SuiteTM version 6.5 and tried
Figure 1. PCA plot of GBM samples with methylation data. Red: G-CIMP negative, Blue: G-CIMP positive. Methylation sites with std. deviation
.0.2 are selected to generate this graph.
doi:10.1371/journal.pone.0062982.g001
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different parameter choices for the SVM algorithm. To compute
DEGs, we used one-way ANOVA.
Validation on External Data Set
To validate the age-specific signatures derived from the TCGA
data set, we obtained gene expression profiles of GBM samples
from the REMBRANDT database (http://caintegrator-info.nci.
nih.gov/rembrandt). We predicted the G-CIMP status of these
samples as described above. There were 153 G-CIMP negative
samples (27 old, 15 young, and 111 intermediate). Due to the small
sample size, we were unable to compute statistically significant
age-specific DEGs on this data set. We, therefore, filtered in the
age-specific genes at the transcriptional level derived from both
TCGA Agilent 244 K G4502A and Affymetrix U133A data sets
(hereafter the TCGA age signature) in the REMBRANDT data
set to create a filtered data set. We clustered the filtered data set via
hierarchical clustering to see if old and young samples would be
separated by TCGA age signature. We also clustered the
unfiltered REMBRANDT data set (i.e., all genes) and compared
both results. As a more quantitative approach, we also built an
ANOVA model on filtered and unfiltered REMBRANDT data
sets to compute how much of the variation could be explained by
the age group (i.e., old and young). We built a 3-way ANOVA by
using gender, age group, and sample source institute as categorical
factors. We used PartekH Genomics SuiteTM version 6.6 for
clustering and building ANOVA model.
Results
Age is an Independent Significant Prognostic Factor for
Survival within G-CIMP Negative GBMs
Age is known to be an independent significant prognostic factor
for survival in GBMs [1,22]. Our multivariate Cox regression
analysis on G-CIMP negative GBM samples also demonstrated
that age is an independent significant factor for survival within G-
CIMP negative GBM patients (p-value,5.02e-07, Table S3). The
Kaplan-Meier plot also shows that there is significant survival
difference between old and young GBM samples (log-rank
p#2.42e-08, Figure 2). Of note, our results show that GBM
molecular subtypes are not a significant factor for survival as
previously reported [15].
Age-specific Signature at the Transcriptional Level
We computed age-specific DEGs by using both t-test and linear
regression. DEGs found by linear regression mostly contain DEGs
found by t-test in all three platforms suggesting that the use of all
samples gives more power to the analysis (Table 2). Using linear
regression, we found 1749, 909, and 91 DEGs in Affymetrix
U133A, Agilent G4502A, and Affymetrix Human Exon 1.0
platforms, respectively (FDR,0.05, Table S4). The low number of
DEGs in the exon data set is possibly due to the lower sample size
compared with the other data sets. There are 334 DEGs found
both in Agilent G4502A and Affymetrix U133A platforms. Among
these DEGs, seven of them (SOD2, GTPBP4, TPST1, GNA12,
SIM2, ZFP2, and SLC22A5) have also age-specific differential
expression in normal brain tissues based on a data set described in
[32]. Two hundred and thirty of these genes (69%) are
upregulated in older GBMs. There are fourteen genes that were
found by both tests in all three platforms (upregulated in old:
PRUNE2, TMEM144, SLC14A1; downregulated in old:
H2AFY2, ENOSF1, SFRP1, RANBP17, SVIL, TUSC3, AT-
F7IP2, FZD6, TSPYL5, DLK1, HIST3H2A). A number of these
genes are of apparent interest for GBM biology such as TUSC3,
which is a tumor suppressor candidate gene and known to be
hypermethylated in GBMs [33]. Additionally, SFRP1 and FZD6
are in the Wnt signalling pathway [34].
Age-specific microRNA Expression Signature
We applied ranked-based linear regression and found 19
differentially expressed microRNAs (FDR,0.05) (ebv-miR-
BART1-5p, hsa-miR-422b, hsa-miR-507, hsa-miR-147, ebv-
miR-BHRF1-2, hsa-miR-620, hsa-miR-554, hsa-miR-625, hsa-
miR-661, hcmv-miR-UL70-5p, hsa-miR-325, hsa-miR-453, hsa-
miR-552, hsa-miR-558, hsa-miR-223, hsa-miR-302c, hsa-miR-
142-5p, hsa-miR-649, hsa-miR-142-3p). All these microRNAs are
downregulated in older GBMs. We used the mirWalk database
[35] to find experimentally validated targets of these microRNAs.
We found 172 experimentally validated target genes (Table S5).
Two of these target genes are upregulated in older GBMs (LOX,
VEGFA). VEGFA is known to be upregulated in older GBMs
[16,36]. LOX and HIF-1 act in synergy to help tumor cells adapt
to hypoxia [37].
Age-specific Signature at the Epigenetic Level
We found 389 age-specific DMGs by using ranked-based linear
regression (Table S6). Ninety-eight percent of these DMGs are
hypermethylated in the older GBMs. Seventeen genes that are
hypermethylated in the older GBMs are polycomb group protein
target genes (PCGTs) (Table S7, Fisher’s exact test p-value,1.0e-
10). Hypermethylation of PCGTs has been previously shown to be
associated with aging [38]. We subtracted out genes that are
normally methylated in an age specific manner based on previous
data sets [39], and found 184 and four genes that are uniquely
hypermethylated in the old and young GBMs, respectively (Table
S8). Eighteen of the GBM-specific DMGs exist in the Pubmeth
database [40], which stores genes that are known to undergo
methylation in cancer (Table S9, Fisher’s exact test p-
value,1.27e-05). Eleven genes are both differentially expressed
(Agilent and Affymetrix U133A platforms) and methylated with
respect to age (Table S10). Seven of them are hypermethylated
and downregulated in older GBMs (MYO1B, PRKCB1, VRK2,
FZD6, DLK1, SLC25A21, MSC). We also found three differen-
tially methylated microRNAs (hsa_miR_196b, miR_34b, and
miR_34c), all of which were hypermethylated in the old group.
Age-specific Signature at the Genetic Level
Each copy number/SNP data set was analyzed in Nexus
independently. Figure 3a–c shows the whole genome copy number
alteration (CNA) profiles of the old and young groups on these
data sets. We found 1044 and 455 differentially altered genes
(DAGs) in Affymetrix SNP 6 and HG-CGH 244A platforms,
respectively (Table S11). The DAG list found in SNP 6 platform
covers 88% of DAGs found in HG-CGH 244A. We could not
detect any DAGs on HumanHap550 platform possibly due to the
low resolution of this data set. We found the largest DAG list on
SNP 6 platform possibly because of its high resolution.
Analyzing the SNP 6 data set, we detected differential deletions
only on chromosome 10 for 722 genes. We observed that the old
group had a higher frequency of deletion than the young group.
We found 321 differentially amplified genes on chromosome 7
with a higher frequency in the old group than the young group
and one gene on chromosome 1q (CFHR3) with a higher
frequency in the young group than the old group. The high
frequency of chromosome 10 deletion and chromosome 7
amplification in the old group, and high frequency of chromosome
1q amplification in the young group have also been reported in a
study that compared a cohort of pediatric GBMs with adult GBMs
[41].
Age-Specific Signatures of Glioblastoma
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We compared the list of DAGs on SNP 6 and the list of DMGs,
and found three genes that are both heterozygously deleted and
hypermethylated in the old group (HHEX, ITGA8, RASGEF1A).
Among these genes, HHEX is downregulated in older GBMs.
HHEX is known to downregulate VEGF and VEGF receptors
[42]. We also observed a significant negative correlation between
HHEX and VEGFA expression levels in the TCGA data set
(Table S12).
We also compared the list of DAGs on SNP 6 and the list of
DEGs found on both Agilent G4502A and Affymetrix U133A
data sets. There are 21 genes that are deleted and downregulated,
and 7 genes that are amplified and upregulated in the old group
(Table S13).
We also analyzed somatic mutations derived from whole exome
sequence data. In general, there are more mutations in the old
group (Table 3). There are two genes that stand out: TP53 is
mutated in 19 old samples and in only one young sample (Fisher’s
exact test p-value,0.068). GRM3 is mutated in 3 out of 12 young
samples and none of the old samples (Fisher’s exact test p-
value,0.01645).
Motif Enrichment Analysis
We analyzed the promoter regions of differentially expressed
genes appear in Affymetrix U133A and Agilent G4502A data sets.
We have found several motifs statistically enriched in the promoter
regions of these genes including HIF-1A and MYC (FDR#0.05
Table S14).
Functional Analysis of Age-specific DEGs
We ran a GSEA on the old and young groups to discover
upregulated gene sets for each group (Table S15). GSEA analysis
found that the younger GBMs maintain an active regulation of G1
entry checkpoint in cell cycle (p,0.05) and have a quiescent
phenotype (p,0.03). Older GBMs uphold a strong oxygen
depletion environment (p,0.04) that induces the hypoxia induc-
ible factor signaling as indicated by three up-regulated HIF
signatures (p,0.05) (Table S15). Furthermore, carbohydrate
metabolism with over-expressed glycolysis and glucagon signaling
reactomes are enhanced in older GBMs. Younger GBMs showed
enrichment of P38_MAPK signaling (p,0.01) and upregulated
targets of MYC (p,0.04), BMYB signature (p,0.02), and
enhanced stem cell signatures (p,0.02) (Table S15). Moreover,
a premalignant signature driven by hepatic stem cell marker,
epithelial cell adhesion molecular (EpCAM) is enhanced in
younger GBMs (p,0.04) whereas older GBMs showed more
advanced tumor profiles (p,0.01) and more invasive expression
signatures regulated by integrin-mediated cell migration (p,0.03).
Additionally, glioblastoma tumor in young patients showed an
increased TNF signaling (p,0.05) and protein translational
Figure 2. Kaplan-Meier plot between old, young, and middle-aged GBM samples.
doi:10.1371/journal.pone.0062982.g002
Table 2. Number of differentially expressed genes between
Old and Young GBM samples for three transcriptomic
platforms.
T-test1
Linear
regression1 Common
Affymetrix HT HG U133A 630 1749 595
Affymetrix Human Exon 1.0 ST 62 91 40
Agilent 244K G4502A 348 909 313
Common (U133A and
G4502A)
130 334 115
Common (all three
platforms)2
17 40 14
The last row shows the number of differentially expressed genes found in all
three platforms.
1In each test, FDR#0.05 threshold is applied.
2Shows the number of differentially expressed genes found in all three
platforms.
doi:10.1371/journal.pone.0062982.t002
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activities (p,0.03), as indicated by the formation of translation
initiation complex involving 43S unit (Table S15).
We also ran DAVID on upregulated genes that appear in the
Affymetrix U133A and Agilent G4502A data sets. We found
enrichment in several GO terms such as ‘‘response to hypoxia’’ (p-
value,0.00123, enriched genes: VEGFA, SOD2, BNIP3,
SLC11A2, EGLN3, PLOD2, NOL3, and ALDOC); ‘‘vasculo-
genesis’’ (p-value,0.088, enriched genes: VEGFA, NTRK2, and
QKI) (Table S16).
Cross-validation on TCGA Data Set
We applied 10-fold cross-validation and built a model based on
age-specific DEGs on training data and used this model to predict
the old/young status of the remaining test samples. The model
achieved over 77% prediction accuracy. For comparison, we also
used the same algorithm to build a model based on the molecular
subtype-specific DEGs of training data. This model predicted
about 64% of prediction accuracy.
Validation on External Data Set
We obtained the gene expression profiles of G-CIMP negative
GBM samples from the REMBRANDT database to validate our
findings. We created a filtered REMBRANDT data set by filtering
in the TCGA age signature (i.e. age-specific differentially
expressed genes derived from both TCGA Affymetrix U133A
and Agilent 244 K G4502A data sets via linear regression). We
Figure 3. Genome-wide copy number alteration profiles of old and young GBM samples. Data are from (a) Agilent Human Genome CGH
Microarray 244A (Memorial Sloan-Kettering Cancer Center), (b) Affymetrix Genome-Wide Human SNP Array 6.0 (Broad Institute of MIT and Harvard),
(c) Illumina 550 K Infinium HumanHap550 SNP Chip (HudsonAlpha Institute for Biotechnology) platforms (chr 1–23). Green bars represent
amplification and red bars represent deletion. The height of each bar represents the frequency of the alteration in the group. The differentially
amplified genes are in chromosome 7 and differentially deleted genes are in chromosome 10.
doi:10.1371/journal.pone.0062982.g003
Table 3. Number of mutated genes in old and young GNEG GBMs.
Number of samples1 Number of mutated genes in Old Number of mutated genes in Young
.0 3038 720
.1 561 37
.2 159 3 (GRM3, TTN, PTEN)
.3 49 0
.6 8 (PTEN, EGFR, MUC16, TTN, TP53, RYR2, SLIT3, LRP2) 0
.8 5 (PTEN, EGFR, MUC16, TTN, TP53) 0
.15 2 (PTEN, TP53) 0
1Shows number of old of young samples each gene is mutated. For instance, there are 3038 genes that are mutated in at least one old sample (see first row) and PTEN is
mutated in more than 15 old samples (see last row).
doi:10.1371/journal.pone.0062982.t003
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clustered both filtered (Figure 4-A) and unfiltered (i.e. all genes)
REMBRANDT data sets (Figure 4-B). To create a reference point,
we also clustered old and young GBMs in TCGA Affymetrix
U133A data set based on the TCGA age signature (Figure 4-C).
We observed that the separation between old and young groups is
more apparent in the cluster on filtered data set than the
separation on the unfiltered data set (Figure 4). We also observed
that the separation of old and young samples in the clustering of
filtered data set are very similar to the separation of old and young
samples in TCGA Affymetrix data set (Figure 4). Additionally, we
built a 3-way ANOVA model on both filtered and unfiltered
REMBRANDT data sets by using the categorical factors of age
group (i.e., old and young), gender, sample source institute to
compute how much of the variation in gene expression is
explained by each factor (Figure 5, 6). The results show that age
group explains the majority of the variation in the filtered data set,
whereas it could not explain the variation in the unfiltered data set.
We also checked whether TCGA DEGs have the same direction
of regulation (up or down) in REMBRANDT data set. We applied
age-specific linear regression to compute p-value for TCGA DEGs
in REMBRANDT data set and created a gene list for both
FDR,0.05 and unadjusted p-value,0.05 thresholds. There were
55 and 148 genes in these gene lists, respectively, which had 100%
consistency with respect to the directionality of regulation in
TCGA and REMBRANDT data sets.
Discussion
Age has consistently been shown to be one of the most powerful
prognostic factors for survival in patients with malignant gliomas
with younger patients generally living much longer than older
patients. The negative effects of age seen in a number of systemic
cancers have often been ascribed to the physiological stress of
metastatic cancer in the setting of concurrent medical problems
leading to an increased rate of medical related deaths [43].
Additionally, the poor tolerance of older patients to aggressive
toxic systemic chemotherapy often results in either treatment-
related complications and/or suboptimal tumor treatment [44].
These clinical variables do not, however, adequately explain the
profoundly negative effect of age in patients with GBM since such
patients almost never have metastatic disease and do not usually
die of concurrent medical problems. Furthermore, the marginal
effects of systemic chemotherapy in patients with GBMs means
that patients are generally treated less aggressively than patients
with systemic cancer and the amount of chemotherapy that GBM
patients receive has little impact on overall survival. Furthermore,
there are few data to suggest that involved field radiotherapy, the
one effective treatment for GBM, is associated with increased
mortality in older versus younger patients. The lack of a clinical
explanation for the poorer survival of older patients with GBM,
together with the growing appreciation of the heterogeneous
nature of the disease, leads to the hypothesis that the impact of age
on survival may be do to a difference in the biology of GBMs in
older patients compared to that in younger patients.
There have been a relatively large number of studies over the
last decade demonstrating that GBM is a heterogeneous tumor
with the most recent studies suggesting that there are at least four
major molecular subtypes of GBM based on gene expression
profiling [15]. Those major subtypes, however, do not account for
Figure 4. Hierarchical clustering of GBM samples in the REMBRANDT and TCGA data sets. (A) Clustering of old and young REMBRANDT
GBM samples based on the expression profiles of age-specific genes derived from both TCGA Affymetrix U133A and Agilent G4502A data sets. (B)
Clustering of old and young REMBRANDT GBM samples based on the expression profiles of all genes in the REMBRANDT data set. (C) Clustering of the
old and young TCGA GBM samples based on the expression profiles of age-specific genes derived from both TCGA Affymetrix U133A and Agilent
G4502A data sets.
doi:10.1371/journal.pone.0062982.g004
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Figure 5. Source of variation of expression profiles of age-specific genes in the REMBRANDT data set. The x-axis shows the components
of the 3-way ANOVA model and the y-axis shows the median signal to noise ratio. The ANOVA model is built based on the expression profiles of the
TCGA age-specific genes in REMBRANDT data set. The TCGA age-specific genes are the intersection of DEGs computed on TCGA Affymetrix U133A
and Agilent G4502A data sets.
doi:10.1371/journal.pone.0062982.g005
Figure 6. Source of variation of expression profiles of all genes in the REMBRANDT data set. The x-axis shows the components of the 3-
way ANOVA model and the y-axis shows the median signal to noise ratio. The ANOVA model is built based on the expression profiles of all genes in
REMBRANDT data set.
doi:10.1371/journal.pone.0062982.g006
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the effect of age on survival. Recently, however, the G-CIMP
positive subgroup of the proneural subtype of GBM was described
based on a pattern of differential genomic methylation [22]. G-
CIMP positive GBM patients tend to be younger and have a
significantly longer survival than the G-CIMP negative GBMs thus
accounting for some of the age-associated effects on survival [22].
Nevertheless, our data demonstrates that age remains a powerful
predictor of survival amongst G-CIMP negative tumors. Thus, we
sought to elucidate a biological basis for this age–related effect. To
do so, we integrated the high-throughput transcriptomic, genetic,
and epigenetic profiles of about 425 GBM samples in the TCGA
project to find age-specific signatures at the transcriptional,
genetic, and epigenetic levels and found such differences at all
levels.
We observed a relative small number of DAGs that consistently
differentiated old versus young GBMs. Specifically we found that
chromosome 10 deletion and chromosome 7 amplification was
found commonly in the old group whereas there was a relatively
high frequency of chromosome 1q amplification in the young
group, observations that have been previously reported in a study
that compared a cohort of pediatric GBMs with adult GBMs [41].
In contrast to the relatively few consistent genomic changes
between each group of tumors, we did observed a large age-
specific signature at the transcriptional level. We observed a major
overlap between the DEGs found in Affymetrix U133A and
Agilent G4502A platforms, although not surprisingly, each
platform had unique DEGs as described in [45]. We observed
fewer DEGs on the Affymetrix Human Exon 1.0 platform possible
due to the lower sample size in this platform.
We applied 10-fold cross validation on TCGA U133A data set
to validate age-specific DEGs. We applied the SVM algorithm to
build a model based on age-specific DEGs of training samples and
applied this model to predict old/young status of the test samples.
This model achieved over 77% prediction accuracy whereas a
model based on molecular subtype-specific DEGs only achieved
64% accuracy.
We also validated age-specific signatures at the transcriptional
level on an external data set. We obtained G-CIMP negative old
and young GBM samples from the REMBRANDT database and
clustered these samples based on the TCGA age signature genes
and all genes. The clustering results showed that the TCGA age
signature could separate the old and young REMBRANDT
samples as well as it separates the old and young TCGA samples.
We also showed that when the TCGA age signature was selected
in the REMBRANDT data set, the majority of the variation could
be explained by age group (i.e., old and young). The age group,
however, could not explain the variation on the entire RE-
MBRANDT data set. We also showed that the upregulated
(downregulated) TCGA DEGs are also upregulated (downregu-
lated) in REMBRANDT data set. These findings indicate that the
TCGA age-specific signature at the transcriptional level is also
age-specific in REMBRANDT data set.
We also observed a large age-specific signature at the epigenetic
level. In particular, we found that about 98% of the DMGs
between the old and young group are hypermethylated in the old
group. There are several studies that show that aging increases
methylation of DNA including cancer-related genes [38,46–48].
The hypermethylated genes in the old group enriched for PCGTs
that are known to be undergo methylation with aging [38]. It has
been also shown that PCGTs in stem cells undergo hypermethyla-
tion with aging and this methylation locks the cell in an
undifferentiated state. Thus, our results are consistent with the
cancer stem cell hypothesis of gliomagenesis being most prevalent
in the older GBMs, in part through hypermethylation of PCGTs.
Figure 7. IPA network of angiogenesis-related genes. Node color represents the expression status based on Affymetrix U133A data set (Red:
Upregulated in old GBMs, Green: Downregulated in old GBMs, Gray: Baseline, White: Unknown, Mix of green and red: both upregulated and
downregulated genes in the complex).
doi:10.1371/journal.pone.0062982.g007
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Obviously, such a hypothesis awaits further experimental valida-
tion, as do the significance and meaning of our other age-specific
epigenetic signatures.
The primary focus of this study was to identify the significant
genomic, genetic and epigenetic signatures between young and old
GBMs for hypothesis generation and future study and although
the annotation and the biological significance of these changes are
well beyond the scope of this manuscript, there is one striking
observation worth noting. We found a significant number of genes
involved in the hypoxic response and in angiogenesis deregulated
in older GBMs compared to younger GBMs. In particular, we
found a remarkable number of genes involved in the regulation of
the proangiogenic protein, VEGF, deregulated in the older GBMs.
This is consistent with older pathology-based studies that have
demonstrated VEGF to be more highly expressed in older GBMs
than in younger GBMs. Examples of the genes we found
deregulated at the expression level or through transcriptional
factor motif activation in older GBM that contribute to VEGF
expression include HIF, HHEX, EGR1, CTCF, HTATIP2, lox,
and DLK1.
To better elucidate the potential angiogenesis-related signaling
aberrations found in older GBMs, we entered into the IPA
network analysis a number of the genes deregulated in older
GBMs at either the transcriptional level or at the TF motif
enrichment level that have been associated with angiogenesis in
the literature. These genes included EGR1 [49], VEGF [50],
CTCF [50], Myc [51], Mycn [52], Sp1 [53], MSX1 [54],
NDRG2 [55], HTATIP2 [56], VRK2 [57], TEAD4 [58],
PKRCB1 [59], HHEX [42], HIF1 [37], DLK1 [60], and Lox
[37]. The resulting IPA-generated network (Figure 7) demon-
strates a complex network with a number of prototypic
deregulated GBM genes (i.e. HIF1A, PDGF, TGF-b, Creb, and
HCG) located at key nodes. Most prominently displayed in this
network is the central role of VEGF.
Thus, it appears that a key biological difference between older
GBMs compared to younger GBMs is the central role of VEGF
and angiogenesis signaling. Although we cannot know for certain
that the more prominent angiogenic profile of older GBMs is
responsible in part for the shorter survival of older patients with
these tumors, there is an extensive literature linking greater
angiogenic potential with decreased survival in GBMs [61–63].
Additionally, the central role of VEGF in the biology of GBMs, as
determined by this computational analysis, may in part explain
recently published data showing that older GBM patients benefit
more from treatment with the VEGF inhibitor, bevacizumab, than
do younger patients [36,64]. These clinical observations have been
considered paradoxical because responses to therapy with
standard cytotoxic agents were historically always greater in
younger GBM patients than in older. Our analysis now gives
biological rationale to these previously unexplained clinical results
with bevacizumab.
In conclusion, we have demonstrated through computational
analyses of high-throughput genomic data from hundreds of
tumors that there are substantial and consistent biological
differences between GBMs found in older patients compared to
those found in younger patients. Although the ultimate biological
meaning and clinical significance of many of these findings await
experimental validation, it appears clear that the pro-angiogenic
phenotype of older GBMs compared to younger GBMs has
biological, clinical, and therapeutic significance. This finding
demonstrates how computational analysis of high-throughput data
of a human tumor can help explain long standing clinical
observations and point the way to more rationale therapeutics
targeted to a specific biological process in selected patients.
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